Hydrohlorotyazyd, enalapril | Co-renitec tablets, 28 pcs.
Special Price
$23.28
Regular Price
$31.00
In stock
SKU
BID494370
Latin name
CO- RENITEC
CO- RENITEC
Latin name
CO- RENITEC
Release form
Tablets.
Packaging
In a blister pack of 7 tablets. In a cardboard box 4 blisters.
Indications
Treatment of hypertension in patients who are shown combination therapy.
Contraindications
anuria.
Hypersensitivity to any component of the drug.
A history of angioedema associated with the use of ACE inhibitors, as well as hereditary or idiopathic angioedema.
Hypersensitivity to other sulfonamide derivatives.
Precautions:
Aortic stenosis.
Cerebrovascular disease (including cerebrovascular insufficiency).
Coronary heart disease.
Chronic heart failure.
Severe systemic diseases of the connective tissue (including systemic lupus erythematosus, scleroderma).
Inhibition of bone marrow hematopoiesis.
Diabetes mellitus.
Hyperkalemia.
Bilateral renal artery stenosis.
Stenosis of a single kidney artery.
Condition after kidney transplantation.
Renal and / or liver failure.
Sodium-restricted diet.
Conditions accompanied by a decrease in circulating blood volume (including diarrhea, vomiting).
Old age.
Use during pregnancy and lactation
Use during pregnancy: The use of Corenitec during pregnancy is not recommended. If pregnancy is detected, Korenitek should be stopped immediately. ACE inhibitors can cause disease or death of the fetus or newborn when prescribed during the second and third trimesters of pregnancy. The use of ACE inhibitors during this period was accompanied by a negative effect on the fetus and newborn, which manifested itself in the form of arterial hypotension, renal failure, hyperkalemia, and / or hypoplasia of the bones of the skull. Perhaps the development of oligohydramnios, apparently due to impaired renal function of the fetus. This complication can lead to contracture of the extremities, deformation of the bones of the skull, including its facial part, and hypoplasia of the lungs. The use of diuretics during pregnancy is not recommended, since it can cause jaundice of the fetus and newborn, thrombocytopenia and, possibly, other undesirable reactions observed in adult patients. If the drug is prescribed during pregnancy, the patient should be warned about the potential risk to the fetus. In those rare cases when the appointment of the drug during pregnancy is considered necessary, periodic ultrasound examinations should be performed to assess the intra-amniotic space. Newborns whose mothers took the drug should be carefully monitored for the development of arterial hypotension, oliguria, and hyperkalemia. Enalapril, passing through the placental barrier, can be removed from the blood of a newborn using peritoneal dialysis with some favorable clinical effect, and theoretically it can be removed by exchange blood transfusion.
Use during lactation: Both enalapril and thiazide diuretics are excreted in breast milk. If the use of the drug is necessary, the patient should stop breast-feeding.
Composition
Active ingredients:
Enalapril maleate 20 mg
hydrochlorothiazide 12.5 mg
Excipients:
Sodium bicarbonate
Lactose aqueous
Corn starch
Corn starch pregelatinized
Iron dye yellow oxide
Magnesium stearate.
Dosage and Administration
Inside.
Arterial hypertension: The initial dose is 1 tablet 1 time per day. If necessary, the dose can be increased to 2 tablets 1 time per day.
Previous treatment with diuretics: At the beginning of therapy with KO-RENITEK, symptomatic hypotension may develop, which occurs more often in patients with impaired water-electrolyte balance due to previous treatment with diuretics. Reception of diuretics should be stopped 2-3 days before the start of therapy with KO-RENITEK.
Renal failure: Thiazides may not be effective diuretics in patients with impaired renal function, and if creatinine clearance is reduced to 30 ml / min or lower (i.e., moderate or severe renal failure), they are ineffective. In patients with creatinine clearance greater than 30, but less than 80 ml / min, KO-RENITEK should be used only after preliminary selection of doses of each component. With a mild degree of renal failure, the recommended initial dose of enalapril when prescribed in monotherapy is from 5 to 10 mg.
Side effects of
In clinical studies, the side effects were usually mild, transient, and in most cases did not require interruption of treatment.
From the cardiovascular system: 1-2% - orthostatic effects, including arterial hypotension rarely - fainting, arterial hypotension, regardless of body position, palpitations, tachycardia, chest pain.
From the side of the central nervous system and peripheral nervous system: often - dizziness, fatigue (usually passed with a dose reduction and rarely required drug withdrawal) 1-2% - asthenia, headaches rarely - insomnia, drowsiness, systemic dizziness, paresthesia, increased irritability.
From the respiratory system: 1-2% - cough rarely - shortness of breath.
From the digestive system: 1-2% - rarely nausea - pancreatitis, diarrhea, vomiting, dyspepsia, abdominal pain, flatulence, constipation, dry mouth.
From the musculoskeletal system: 1-2% - muscle cramps rarely - arthralgia.
Allergic reactions: rarely - angioedema of the face, limbs, lips, tongue, glottis and / or larynx. There are rare reports of the development of angioedema of the intestine in connection with the use of ACE inhibitors, including enalapril.
Dermatological reactions: rarely - Stevens-Johnson syndrome, hyperhidrosis, skin rash, itching.
From the urinary system: rarely - impaired renal function, renal failure.
From the reproductive system: 1-2% - impotence rarely - decreased libido.
On the part of laboratory indicators: possible hyperglycemia, hyperuricemia, hypo- or hyperkalemia, an increase in blood concentration of urea, serum creatinine, an increase in the activity of liver enzymes and / or an increase in serum bilirubin (these indicators usually returned to normal after cessation of Corenitec therapy) - decrease in hemoglobin and hematocrit.
Other: rarely - tinnitus, gout. A symptom complex is described, the possible manifestations of which are fever, serositis, vasculitis, myalgia, myositis, arthralgia / arthritis, a positive test for antinuclear antibodies, acceleration of ESR, eosinophilia and leukocytosis may develop photosensitivity.
Drug interaction
Other antihypertensive agents: When prescribing enalapril in combination with other antihypertensive agents, a cumulative effect may be observed.
Serum potassium: The loss of potassium on the background of thiazide diuretics is usually reduced by enalapril. The serum potassium concentration usually remains within normal limits. The use of potassium supplements, potassium-sparing agents or potassium-containing salts, especially in patients with renal insufficiency, can lead to a significant increase in serum potassium content.
Lithium preparations: ACE diuretics and inhibitors reduce renal excretion of lithium and increase the risk of lithium intoxication. Before using lithium preparations, it is necessary to read the instructions for use of this drug.
Nonsteroidal anti-inflammatory drugs (NSAIDs): Nonsteroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors, may reduce the effect of diuretics and other antihypertensive drugs. Therefore, the hypotensive effect of ACE inhibitors may be diminished when NSAIDs are co-administered, including COX-2 inhibitors. In some patients with impaired renal function receiving NSAIDs, including selective cyclooxygenase-2 inhibitors, concomitant administration of ACE inhibitors may further impair renal function. These changes are usually reversible.
Non-depolarizing muscle relaxants: Thiazide diuretics can enhance the effect of tubocurarin.
Other medicines: Hypotensive effects reduce estrogens, ethanol. Immunosuppressants, allopurinol, cytostatics increase the risk of hematotoxicity.
overdose
Symptoms: Enalapril is a marked decrease in blood pressure, which begins approximately b hours after the administration of the drug, stupor. Concentrations of enalaprilat in the serum exceeding 100-200 times the concentrations observed during the appointment of therapeutic doses occurred after taking 300 and 440 mg of enalapril, respectively.
Hydrochlorothiazide - symptoms caused by loss of electrolytes (hypokalemia, hypochloremia, hyponatremia) and dehydration due to excessive diuresis are observed. If you have previously been prescribed digitalis medications, you may experience an increase in arrhythmias due to hypokalemia.
Storage conditions
In a dry place at a temperature not exceeding 30 РC.
Expiration
2, 5 years.
Active ingredient
Hydrochlorothiazide, Enalapril
dosage form
dosage form
tablets
Merck Sharp and Doom BV, USA
CO- RENITEC
Release form
Tablets.
Packaging
In a blister pack of 7 tablets. In a cardboard box 4 blisters.
Indications
Treatment of hypertension in patients who are shown combination therapy.
Contraindications
anuria.
Hypersensitivity to any component of the drug.
A history of angioedema associated with the use of ACE inhibitors, as well as hereditary or idiopathic angioedema.
Hypersensitivity to other sulfonamide derivatives.
Precautions:
Aortic stenosis.
Cerebrovascular disease (including cerebrovascular insufficiency).
Coronary heart disease.
Chronic heart failure.
Severe systemic diseases of the connective tissue (including systemic lupus erythematosus, scleroderma).
Inhibition of bone marrow hematopoiesis.
Diabetes mellitus.
Hyperkalemia.
Bilateral renal artery stenosis.
Stenosis of a single kidney artery.
Condition after kidney transplantation.
Renal and / or liver failure.
Sodium-restricted diet.
Conditions accompanied by a decrease in circulating blood volume (including diarrhea, vomiting).
Old age.
Use during pregnancy and lactation
Use during pregnancy: The use of Corenitec during pregnancy is not recommended. If pregnancy is detected, Korenitek should be stopped immediately. ACE inhibitors can cause disease or death of the fetus or newborn when prescribed during the second and third trimesters of pregnancy. The use of ACE inhibitors during this period was accompanied by a negative effect on the fetus and newborn, which manifested itself in the form of arterial hypotension, renal failure, hyperkalemia, and / or hypoplasia of the bones of the skull. Perhaps the development of oligohydramnios, apparently due to impaired renal function of the fetus. This complication can lead to contracture of the extremities, deformation of the bones of the skull, including its facial part, and hypoplasia of the lungs. The use of diuretics during pregnancy is not recommended, since it can cause jaundice of the fetus and newborn, thrombocytopenia and, possibly, other undesirable reactions observed in adult patients. If the drug is prescribed during pregnancy, the patient should be warned about the potential risk to the fetus. In those rare cases when the appointment of the drug during pregnancy is considered necessary, periodic ultrasound examinations should be performed to assess the intra-amniotic space. Newborns whose mothers took the drug should be carefully monitored for the development of arterial hypotension, oliguria, and hyperkalemia. Enalapril, passing through the placental barrier, can be removed from the blood of a newborn using peritoneal dialysis with some favorable clinical effect, and theoretically it can be removed by exchange blood transfusion.
Use during lactation: Both enalapril and thiazide diuretics are excreted in breast milk. If the use of the drug is necessary, the patient should stop breast-feeding.
Composition
Active ingredients:
Enalapril maleate 20 mg
hydrochlorothiazide 12.5 mg
Excipients:
Sodium bicarbonate
Lactose aqueous
Corn starch
Corn starch pregelatinized
Iron dye yellow oxide
Magnesium stearate.
Dosage and Administration
Inside.
Arterial hypertension: The initial dose is 1 tablet 1 time per day. If necessary, the dose can be increased to 2 tablets 1 time per day.
Previous treatment with diuretics: At the beginning of therapy with KO-RENITEK, symptomatic hypotension may develop, which occurs more often in patients with impaired water-electrolyte balance due to previous treatment with diuretics. Reception of diuretics should be stopped 2-3 days before the start of therapy with KO-RENITEK.
Renal failure: Thiazides may not be effective diuretics in patients with impaired renal function, and if creatinine clearance is reduced to 30 ml / min or lower (i.e., moderate or severe renal failure), they are ineffective. In patients with creatinine clearance greater than 30, but less than 80 ml / min, KO-RENITEK should be used only after preliminary selection of doses of each component. With a mild degree of renal failure, the recommended initial dose of enalapril when prescribed in monotherapy is from 5 to 10 mg.
Side effects of
In clinical studies, the side effects were usually mild, transient, and in most cases did not require interruption of treatment.
From the cardiovascular system: 1-2% - orthostatic effects, including arterial hypotension rarely - fainting, arterial hypotension, regardless of body position, palpitations, tachycardia, chest pain.
From the side of the central nervous system and peripheral nervous system: often - dizziness, fatigue (usually passed with a dose reduction and rarely required drug withdrawal) 1-2% - asthenia, headaches rarely - insomnia, drowsiness, systemic dizziness, paresthesia, increased irritability.
From the respiratory system: 1-2% - cough rarely - shortness of breath.
From the digestive system: 1-2% - rarely nausea - pancreatitis, diarrhea, vomiting, dyspepsia, abdominal pain, flatulence, constipation, dry mouth.
From the musculoskeletal system: 1-2% - muscle cramps rarely - arthralgia.
Allergic reactions: rarely - angioedema of the face, limbs, lips, tongue, glottis and / or larynx. There are rare reports of the development of angioedema of the intestine in connection with the use of ACE inhibitors, including enalapril.
Dermatological reactions: rarely - Stevens-Johnson syndrome, hyperhidrosis, skin rash, itching.
From the urinary system: rarely - impaired renal function, renal failure.
From the reproductive system: 1-2% - impotence rarely - decreased libido.
On the part of laboratory indicators: possible hyperglycemia, hyperuricemia, hypo- or hyperkalemia, an increase in blood concentration of urea, serum creatinine, an increase in the activity of liver enzymes and / or an increase in serum bilirubin (these indicators usually returned to normal after cessation of Corenitec therapy) - decrease in hemoglobin and hematocrit.
Other: rarely - tinnitus, gout. A symptom complex is described, the possible manifestations of which are fever, serositis, vasculitis, myalgia, myositis, arthralgia / arthritis, a positive test for antinuclear antibodies, acceleration of ESR, eosinophilia and leukocytosis may develop photosensitivity.
Drug interaction
Other antihypertensive agents: When prescribing enalapril in combination with other antihypertensive agents, a cumulative effect may be observed.
Serum potassium: The loss of potassium on the background of thiazide diuretics is usually reduced by enalapril. The serum potassium concentration usually remains within normal limits. The use of potassium supplements, potassium-sparing agents or potassium-containing salts, especially in patients with renal insufficiency, can lead to a significant increase in serum potassium content.
Lithium preparations: ACE diuretics and inhibitors reduce renal excretion of lithium and increase the risk of lithium intoxication. Before using lithium preparations, it is necessary to read the instructions for use of this drug.
Nonsteroidal anti-inflammatory drugs (NSAIDs): Nonsteroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors, may reduce the effect of diuretics and other antihypertensive drugs. Therefore, the hypotensive effect of ACE inhibitors may be diminished when NSAIDs are co-administered, including COX-2 inhibitors. In some patients with impaired renal function receiving NSAIDs, including selective cyclooxygenase-2 inhibitors, concomitant administration of ACE inhibitors may further impair renal function. These changes are usually reversible.
Non-depolarizing muscle relaxants: Thiazide diuretics can enhance the effect of tubocurarin.
Other medicines: Hypotensive effects reduce estrogens, ethanol. Immunosuppressants, allopurinol, cytostatics increase the risk of hematotoxicity.
overdose
Symptoms: Enalapril is a marked decrease in blood pressure, which begins approximately b hours after the administration of the drug, stupor. Concentrations of enalaprilat in the serum exceeding 100-200 times the concentrations observed during the appointment of therapeutic doses occurred after taking 300 and 440 mg of enalapril, respectively.
Hydrochlorothiazide - symptoms caused by loss of electrolytes (hypokalemia, hypochloremia, hyponatremia) and dehydration due to excessive diuresis are observed. If you have previously been prescribed digitalis medications, you may experience an increase in arrhythmias due to hypokalemia.
Storage conditions
In a dry place at a temperature not exceeding 30 РC.
Expiration
2, 5 years.
Active ingredient
Hydrochlorothiazide, Enalapril
dosage form
dosage form
tablets
Merck Sharp and Doom BV, USA
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review